Chemical formula: C₁₃H₂₁N₃O Molecular mass: 235.325 g/mol PubChem compound: 4913
Procainamide is a Group 1A cardiac antiarrhythmic drug. Procainamide (PA) increases the effective refractory period of the atria, and to a lesser extent the bundle of His-Purkinje system and ventricles of the heart. It reduces impulse conduction velocity in the atria, His-Purkinje fibers, and ventricular muscle, but has variable effects on the atrioventricular (A-V) node, a direct slowing action and a weaker vagolytic effect which may speed A-V conduction slightly.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| C01BA02 | Procainamide | C Cardiovascular system → C01 Cardiac therapy → C01B Antiarrhythmics, class I and III → C01BA Antiarrhythmics, class Ia |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| PROCAINAMIDE HCI Solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/Old |
Procainamide is an active ingredient of these brands:
Japan (JP)
Spain (ES)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
